EPZM - Epizyme Comeback Is Likely Price Makes It A Buy March, 30 2021 04:14 AM Epizyme Inc. Epizyme is at a multi-year low. Main cause of disappointment is slow sales of Tazverik. Potential is great with label expansion and epigenetic pipeline. For further details see: Epizyme Comeback Is Likely, Price Makes It A Buy